Dreesen E, et al. - A retrospective cohort study was conducted to investigate the possibility of tailoring infliximab (IFX) treatment intensification based on IFX and antibodies towards infliximab (ATI) concentrations, to guide physicians' clinical decision-making when a patient with Crohn's disease (CD) experiences loss of response. Among patients with CD who lost clinical response, ATI negatively influenced the effectiveness of treatment intensification. ATI concentrations, therefore, could guide clinical decision-making on treatment intensification strategies in patients with CD who lost clinical response.